Drug Trial Radar · NCT05141747
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
Last checked: Nov 19, 2026Latest source record: Feb 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 19, 2022
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive /HER2-low locally advanced or metastatic gastric/ gastroesophageal junction cancer.
Conditions
- Locally Advanced Gastric Cancer
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
Interventions
MRG002Drug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Baseline to study completion, up to 24 months
- Adverse Events (AEs)Time frame: Baseline to 45 days after the lase dose of study treatment.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.